Roivant (NASDAQ: ROIV) CIO sells option shares near $37
Roivant Sciences Ltd.'s President & CIO, Mayukh Sukhatme, exercised stock options for 335,174 common shares at $3.85 per share and subsequently sold all of them across three days (August 19, 20, and 21, 2026) at weighted average prices ranging from $36.48 to $37.30 per share. The total approximate gross sale proceeds were $12.36 million, resulting in an approximate pre-tax spread of $11.07 million. This transaction was disclosed in an SEC Form 4 filing, which noted the options were fully vested and the sales were conducted in multiple transactions within specified price ranges.
107,786 Shares in Roivant Sciences Ltd. $ROIV Purchased by Great Lakes Advisors LLC
Great Lakes Advisors LLC has purchased 107,786 shares of Roivant Sciences Ltd. (NASDAQ:ROIV), valued at approximately $3.8 million, marking a new position for the firm. This comes as institutional investors and hedge funds collectively own 64.76% of the company, despite recent insider selling totaling $87.7 million. Roivant Sciences reported beating quarterly EPS expectations but missed revenue estimates, while analysts maintain a "Moderate Buy" rating with an average price target of $35.14.
Roivant Sciences (ROIV) holder plans new sale after $17M June trade
A holder of Roivant Sciences (ROIV) stock, Mayukh Sukhatme, has filed a Rule 144 notice to sell 172,899 common shares valued at $6.4 million on August 19, 2026, following the exercise of options. This filing also details previous significant sales by Sukhatme, including 500,000 shares sold on June 25, 2026, for over $17 million, and additional sales in August 2026. The sales are being facilitated through Morgan Stanley Smith Barney LLC.
Is Roivant Sciences (ROIV) Fully Valued As First Quarter Results Show A Narrower Loss?
Roivant Sciences (ROIV) reported a narrower net loss in Q1 2026 but saw sales decline. Despite significant share price gains over the past year, a popular narrative suggests the stock is overvalued, with a fair value of $10.00 compared to its current $37.37, largely due to speculative IP litigation and a crowded pipeline. The article questions if the recent upside is already priced in, advising investors to review data to form their own conclusions on valuation.
Is Roivant Sciences (ROIV) Fully Valued As First Quarter Results Show A Narrower Loss?
Roivant Sciences (ROIV) reported a narrower net loss in Q1 2026, though sales decreased. Despite recent share price gains and strong one-year returns, a common narrative suggests the stock is significantly overvalued, with a fair value of $10.00 compared to its current price of $37.37. This valuation concern is primarily linked to the speculative nature of its IP litigation strategy and the perceived overvaluation of its business model.
Insider Selling: Roivant Sciences (NASDAQ:ROIV) Insider Sells 136,942 Shares
Mayukh Sukhatme, an insider at Roivant Sciences (NASDAQ:ROIV), sold 136,942 shares of the company's stock for approximately $5.03 million. Despite this recent sale, Sukhatme still directly owns 18.63 million shares and had prior sales totaling over $19.1 million in August. Roivant Sciences' stock saw a 3.1% increase, nearing its 52-week high, while the company reported an earnings beat but missed revenue estimates for its latest quarter.
Mayukh Sukhatme Sells 284,707 Shares of Roivant Sciences (NASDAQ:ROIV) Stock
Mayukh Sukhatme, an insider at Roivant Sciences (NASDAQ:ROIV), sold 284,707 shares of the company's stock for approximately $10.3 million on August 17th, 2026, reducing his position by 1.51%. This follows two other recent sales by Sukhatme. Despite these insider sales, analysts maintain a "Moderate Buy" consensus rating for ROIV, with the stock trading near its 52-week high after beating quarterly EPS expectations but missing revenue estimates.
Roivant Sciences (NASDAQ:ROIV) Insider Mayukh Sukhatme Sells 243,177 Shares
Roivant Sciences insider Mayukh Sukhatme sold 243,177 shares for approximately $8.81 million, retaining 18.63 million shares. This sale is part of three recent transactions totaling around $24.16 million. Despite a quarterly loss, Roivant Sciences beat analyst estimates and its shares rose 3.1% to near its 12-month high, maintaining a "Moderate Buy" consensus from analysts.
Roivant (ROIV) CIO sells shares after exercising $3.85 options
Roivant Sciences Ltd.'s President & CIO, Mayukh Sukhatme, exercised stock options for 664,826 common shares at $3.85 per share across August 14, 17, and 18, 2026. These shares were then sold in open-market transactions with weighted average prices ranging from $36.23 to $37.18. The total gross sale proceeds were approximately $24.16 million, resulting in an estimated pre-tax spread of $21.60 million.
Roivant Sciences Ltd. (NASDAQ:ROIV) Receives Average Rating of "Moderate Buy" from Brokerages
Roivant Sciences Ltd. (NASDAQ:ROIV) has received an average "Moderate Buy" rating from twelve brokerages, with nine analysts recommending a buy and one a strong buy, resulting in an average 12-month price target of $35.14. Despite the positive analyst outlook, company insiders sold over 2 million shares worth approximately $69.6 million in the last quarter, with CEO Eric Venker being among the sellers. The stock opened at $36.24, close to its 52-week high, with institutional investors owning nearly 65% of the company.
Roivant Sciences stock hits all-time high at 37.06 USD By Investing.com
Roivant Sciences (ROIV) stock reached an all-time high of $37.06, currently trading at $37.14, just 1% below its 52-week high, with a market capitalization of $26.19 billion. The stock has surged 206.52% over the past year, with strong momentum recently, including 33.63% over six months and 66.82% year-to-date. Despite InvestingPro's view that the stock is overvalued relative to its Fair Value, TD Cowen raised its price target to $50, maintaining a Buy rating, citing strong execution and upcoming catalysts.
Roivant Sciences Ltd. (ROIV) Stock Analysis: Exploring a 15.52% Upside Potential with Strong Buy Ratings
Roivant Sciences Ltd. (ROIV) is a biotechnology company attracting investor attention with strong buy ratings and a potential 15.52% upside, despite current unprofitability. Analysts have an average target price of $41.82, and its clinical-stage pipeline, including treatments for autoimmune diseases, shows promise. While technical indicators suggest it might be overbought, the company's focus on innovative therapies makes it a compelling, albeit risky, long-term investment.
Roivant (NASDAQ: ROIV) holder eyes new sale after tens of millions sold
An affiliate of Roivant Sciences Ltd. (NASDAQ: ROIV), Mayukh Sukhatme, has filed a Form 144 indicating an intention to sell 284,707 shares of common stock for approximately $10.3 million on August 17, 2026, through an exercise of options. This follows previous sales by Sukhatme totaling over 1.2 million shares for tens of millions of dollars in the preceding three months. The filing provides details on both the upcoming sale and prior transactions, which include sales on June 25, June 26, and August 14, 2026.
Roivant Sciences (NASDAQ:ROIV) Sets New 1-Year High - Here's Why
Roivant Sciences (NASDAQ: ROIV) stock reached a new 52-week high of $37.19 on Monday, trading at $36.0760 with a market capitalization of $26.17 billion. Analysts maintain a "Moderate Buy" consensus, with Guggenheim and HC Wainwright recently raising price targets to $42 and $41, respectively, although the consensus target is $35.14. Institutional investors hold 64.76% of the company, with some increasing their stakes, while insiders sold over 2 million shares worth $69.6 million in the last quarter.
Roivant Sciences stock hits all-time high at 37.06 USD By Investing.com
Roivant Sciences (ROIV) stock reached an all-time high of $37.06, now trading at $37.14 with a market capitalization of $26.19 billion, marking a 206.52% increase over the past year. Despite its strong performance and recent narrower-than-expected loss in fiscal Q1, InvestingPro analysis suggests the stock is overvalued. Analysts like TD Cowen have raised price targets, anticipating future catalysts for growth.
Roivant Sciences stock hits all-time high at 37.06 USD By Investing.com
Roivant Sciences (ROIV) stock reached an all-time high of $37.06, currently trading at $37.14, with a market capitalization of $26.19 billion. The company has seen significant growth, with its stock price surging 206.52% over the past year. Despite an InvestingPro analysis suggesting the stock is overvalued, TD Cowen recently raised its price target to $50, maintaining a Buy rating.
How Investors May Respond To Roivant Sciences (ROIV) Narrowing Losses Despite Weaker Quarterly Revenue
Roivant Sciences (ROIV) reported a narrowed net loss of US$189.84 million, down from US$223.36 million, despite a decrease in first-quarter revenue to US$1.44 million from US$2.17 million. This suggests improved cost control or operating efficiencies. Investors are urged to consider how this affects the company's investment narrative, particularly its ongoing heavy R&D needs and share repurchase program, against the backdrop of limited current sales and long-term revenue and earnings forecasts.
How Investors May Respond To Roivant Sciences (ROIV) Narrowing Losses Despite Weaker Quarterly Revenue
Roivant Sciences (ROIV) reported narrowing net losses in Q1 2026 despite weaker revenue, suggesting improved cost control. While the reduced loss is a positive sign, the investment narrative remains focused on clinical and regulatory progress of its pipeline, with ongoing R&D expenses and share repurchases being key factors for investors to consider. The company's future hinges on its ability to advance its autoimmune and rare disease pipeline to justify its high R&D costs and limited current sales.
Royal Bank of Canada Decreases Position in Roivant Sciences Ltd. $ROIV
Royal Bank of Canada significantly reduced its stake in Roivant Sciences Ltd. by 82.1% in the first quarter, selling over 500,000 shares. Despite this, institutional investors still hold a substantial 64.76% of the company, and analysts generally maintain a "Moderate Buy" rating with a target price of $35.14. Insider selling also occurred, with key directors divesting shares, although insiders collectively still own 8.8% of the stock.
Empowered Funds LLC Buys 267,686 Shares of Roivant Sciences Ltd. $ROIV
Empowered Funds LLC significantly increased its stake in Roivant Sciences Ltd. (NASDAQ:ROIV) by 1,468.5% in the first quarter, acquiring an additional 267,686 shares to bring its total holdings to 285,915 shares, valued at approximately $7.92 million. Despite this institutional buying, Roivant insiders have sold 2.06 million shares worth about $69.6 million in the last three months. The stock opened at $36.20, near its 52-week high, and analysts maintain a "Moderate Buy" consensus with an average price target of $35.14, although Citigroup recently raised its target to $46.00.
Handelsbanken Fonder AB Has $6.27 Million Position in Roivant Sciences Ltd. $ROIV
Handelsbanken Fonder AB significantly increased its stake in Roivant Sciences Ltd. during the second quarter, now holding 177,209 shares valued at $6.27 million. Institutional investors collectively own 64.76% of Roivant's stock, despite recent insider selling totaling approximately 2.06 million shares. Analysts maintain a "Moderate Buy" rating for ROIV with an average price target of $35.14.
How Roivant Sciences Ltd. (ROIV) Affects Rotational Strategy Timing
This article analyzes Roivant Sciences Ltd. (ROIV) through AI-generated trading strategies and multi-timeframe signal analysis. It highlights a near-term strong sentiment transitioning to a long-term positive bias, with an exceptional 28.3:1 risk-reward setup. The analysis provides specific entry, target, and stop-loss zones for various trading strategies, indicating potential for an 8.0% gain versus a 0.3% risk.
How Roivant Sciences Ltd. (ROIV) Affects Rotational Strategy Timing
This article analyzes Roivant Sciences Ltd. (NASDAQ: ROIV) and its impact on rotational strategy timing, highlighting a strong near-term sentiment with a long-term positive bias. It details exceptional risk-reward setups and provides three distinct AI-generated trading strategies (Position, Momentum Breakout, and Risk Hedging) with multi-timeframe signal analysis for various holding periods. The report also lists support and resistance levels across near, mid, and long-term horizons.
Roivant Sciences (ROIV) Is Up 7.2% After Narrower Net Loss Despite Lower Quarterly Revenue
Roivant Sciences (ROIV) reported a narrower net loss in Q1 2026, reaching US$189.84 million compared to US$223.36 million a year earlier, despite a dip in revenue to US$1.44 million. This improvement in net loss and basic loss per share suggests progress in efficiency and cost control. The company's investment narrative continues to hinge on its late-stage immunology pipeline and upcoming clinical and regulatory milestones, with its long-term forecast projecting $1.8 billion revenue and $337.8 million earnings by 2029.
Citi Maintains Roivant Sciences(ROIV.US) With Buy Rating, Raises Target Price to $46
Citi has reiterated its Buy rating on Roivant Sciences (ROIV.US) and increased its target price to $46. This positive adjustment suggests increased confidence from Citi in the company's future performance.
Bank of America Corp DE Has $87.64 Million Stock Position in Roivant Sciences Ltd. $ROIV
Bank of America Corp DE increased its stake in Roivant Sciences Ltd. (NASDAQ:ROIV) by 8% in the first quarter, now holding 3.16 million shares valued at $87.6 million. Despite positive pipeline developments and a "Moderate Buy" analyst consensus, company insiders sold approximately $69.6 million worth of stock in the last quarter. Institutional investors and hedge funds collectively own 64.76% of ROIV.
Roivant Sciences (ROIV) Is Up 7.2% After Narrower Net Loss Despite Lower Quarterly Revenue
Roivant Sciences (ROIV) saw its stock rise by 7.2% after reporting a narrower net loss of US$189.84 million in Q1 2026, despite a decrease in revenue to US$1.44 million. The company's investment narrative continues to focus on its late-stage immunology pipeline and upcoming clinical and regulatory milestones, which are crucial for validating its long-term strategy and justifying ongoing R&D expenses. Analysts are evaluating the impact of these results on future expectations and the stock's fair value.
Roivant Sciences Ltd. 2026 Q1 - Results - Earnings Call Presentation (NASDAQ:ROIV) 2026-08-06
This article announces the publication of Roivant Sciences Ltd.'s 2026 Q1 earnings call presentation. The company reported an EPS of -$0.34, beating estimates by $0.02, and revenue of $1.44M, which missed expectations by $897.33K, representing a 33.55% year-over-year decrease. The slide deck provides details discussed during the earnings call.
Sei Investments Co. Acquires 33,508 Shares of Roivant Sciences Ltd. $ROIV
Sei Investments Co. significantly increased its stake in Roivant Sciences Ltd. by 38.6% in the first quarter, adding 33,508 shares to reach a total of 120,326 shares valued at $3.33 million. Despite this institutional accumulation, company insiders, including CEO Eric Venker, have been actively selling shares, with over 2.05 million shares worth $69.6 million sold in the last quarter. Analysts maintain a "Moderate Buy" rating for Roivant Sciences, with several recent price target increases, while the stock trades near its 52-week high.
Roivant Sciences (ROIV) Stock Rally Leans On Cash As Losses Persist
Roivant Sciences (ROIV) stock has rallied despite recent losses, driven by its strong cash position of nearly US$4.0 billion and a promising late-stage autoimmune pipeline. While the company recorded a net loss of US$189.84 million in Q1 2027, investors are focusing on pipeline milestones and cash strength, overlooking the high R&D burn. The market sentiment is split between bullish views on pipeline conversion and bearish concerns over persistent losses and reliance on one-off financial gains.
Assenagon Asset Management S.A. Acquires 1,286,464 Shares of Roivant Sciences Ltd. $ROIV
Assenagon Asset Management S.A. increased its stake in Roivant Sciences Ltd. (NASDAQ:ROIV) by 18.2% in the second quarter, acquiring an additional 1.29 million shares, bringing its total holdings to 8.36 million shares valued at approximately $296 million. Other institutional investors also significantly increased their positions, while company insiders, including CEO Eric Venker, sold substantial amounts of stock. Analysts maintain a "Moderate Buy" rating for Roivant Sciences, with a consensus price target of $33.59, though the stock recently traded near its 52-week high.
Roivant Sciences Ltd. Stock 12‑Month Price Target Raised to $39.73, Implies 15% Upside
Roivant Sciences Ltd. (ROIV) has seen its average 12-month price target raised from $38.91 to $39.73 by 11 analysts, with forecasts ranging from $34 to $50 per share. This new target implies a potential upside of approximately 15% based on the August 5th closing price. The consensus rating for ROIV remains "Buy" among 13 analysts, comprising 12 Buys and 1 Hold.
Roivant Sciences Ltd. 2026: Revenue $1.44M, EPS ($0.26) — 10-Q Summary
Roivant Sciences Ltd. (ROIV) reported its 2026 quarterly results, showing revenue of $1.44 million and a diluted loss per share of ($0.26). This represents a decrease in revenue and an improvement in diluted EPS compared to the prior-year quarter. The company also highlighted pipeline progress for brepocitinib, clinical momentum for IMVT-1402 and mosliciguat, and preparations for a commercial launch of brepocitinib.
Earnings call transcript: Roivant misses Q1 2026 EPS as pipeline build accelerates
Roivant Sciences reported a wider-than-expected first-quarter loss, with EPS of -$0.75 against an analyst forecast of -$0.60, as the company continued heavy spending on R&D and commercial preparation. Despite the miss, management framed the period as a "calm before the storm," anticipating a "jam-packed second half" of 2026 with several key pipeline readouts and potential product launches, including brexpiprazole for dermatomyositis. The company emphasized its strong cash position, recent Moderna settlement payment, and a rich catalyst calendar, maintaining investor confidence with significant stock performance over the past year.
Roivant Sciences Releases Q1 2026 Financial Results
Roivant Sciences Ltd. reported a narrowed Q1 2026 diluted EPS loss of -$0.26, a 21.2% improvement year-over-year, despite a net loss of $189.8M and a revenue decline to $1.4M. The clinical-stage biopharmaceutical company continues to focus on advancing its drug pipeline, with Wall Street analysts maintaining a positive outlook on its prospects.
Roivant Sciences earnings beat by $0.04, revenue fell short of estimates
Roivant Sciences (NASDAQ: ROIV) reported second-quarter earnings per share of $-0.260, surpassing analyst estimates by $0.04. However, the company's revenue of $1.44 million fell short of the consensus estimate of $2.32 million. Despite the revenue miss, Roivant Sciences' stock has shown strong performance, increasing by 21.150% in the last three months and 199.570% in the last 12 months.
Roivant Sciences Ltd. Reports Earnings Results for the First Quarter Ended June 30, 2026
Roivant Sciences Ltd. reported its financial results for the first quarter ended June 30, 2026. The company experienced a decrease in sales to USD 1.44 million from USD 2.17 million in the prior year. Despite lower sales, the net loss narrowed to USD 189.84 million compared to USD 223.36 million a year ago, with basic and diluted loss per share from continuing operations also improving.
Roivant Sciences Q1 2027 Earnings Call Transcript
Roivant Sciences held its Q1 2027 earnings call, highlighting significant progress and an exciting pipeline for the coming year. The company is on track for the late September launch of brepocitinib for dermatomyositis and has initiated a Phase III study for cutaneous sarcoidosis. Roivant also received a $950 million settlement payment from Moderna and is pursuing additional litigation against Pfizer and BioNTech.
Roivant Sciences (NASDAQ: ROIV) details $771.6M Moderna settlement windfall
Roivant Sciences (NASDAQ: ROIV) reported a net loss of $290.6 million for the quarter ended June 30, 2026, driven by increased research and development expenses. The company's liquidity was significantly bolstered by a $771.6 million litigation settlement receivable from Moderna, which was collected in July 2026. Roivant is advancing several late-stage drug candidates, including brepocitinib and IMVT-1402, with numerous clinical readouts anticipated from late 2026 through 2028.
Earnings Flash (ROIV) Roivant Sciences Ltd. Reports Q1 Revenue $1.4M, vs. FactSet Est of $2.1M
Roivant Sciences Ltd. reported Q1 revenue of $1.4 million, which fell short of FactSet's estimated $2.1 million. This financial update indicates that the biopharmaceutical company's revenue performance for the quarter did not meet analyst expectations. The article provides a snapshot of the company's recent financial results and pipeline developments.
Roivant Sciences Ltd. (ROIV) Tops Q1 EPS by 4c
Roivant Sciences Ltd. (ROIV) reported its Q1 earnings, beating analyst EPS estimates by $0.04 with a reported EPS of ($0.26) against an estimated ($0.30). However, the company's revenue for the quarter came in at $1.44 million, falling short of the consensus estimate of $2.32 million.
(ROIV) and the Role of Price-Sensitive Allocations
This article provides an AI-generated analysis of Roivant Sciences Ltd. (NASDAQ: ROIV), highlighting weak near and mid-term sentiment but a strong long-term outlook. It details three institutional trading strategies—Position Trading, Momentum Breakout, and Risk Hedging—with specific entry, target, and stop-loss levels. The analysis also includes multi-timeframe signal strengths and support/resistance levels.
Roivant Sciences Ltd. Revenue Breakdown – NASDAQ:ROIV
This article provides a brief overview of Roivant Sciences Ltd.'s revenue breakdown for the last fiscal year. The company generated $8.26 million USD, with its primary revenue stream coming from the "Medicines and Technologies" segment. The United Kingdom was the largest regional contributor to its revenue.
Roivant Sciences Ltd (ROIV) Financial Health: Profitability & Balance Sheet Analysis
This article provides an analysis of Roivant Sciences Ltd (ROIV)'s financial health, indicating a current financial score of 6.75, ranking 131 out of 155 in the Pharmaceuticals industry. The company's financial status is described as robust, with low operating efficiency. Latest quarterly revenue decreased by 66.71% year-over-year, and net profit experienced a 246.75% year-over-year decrease.
Roivant Sciences Ltd (ROIV) Valuation: PE, PB & Fair Value Analysis
This article provides a valuation analysis for Roivant Sciences Ltd (ROIV), stating its current valuation score is 7.28, ranking 132 out of 155 in the Pharmaceuticals industry. The P/E ratio is reported as -79.90, which is below its recent high and above its recent low. Key valuation metrics like P/B, P/S, and P/CF data have not been disclosed by the company.
Form 4 Roivant Sciences Ltd. For: 29 July By Investing.com
This article from Investing.com announces the filing of Form 4 for Roivant Sciences Ltd. on July 29th. It is a brief, informational piece indicating a regulatory filing has occurred, primarily serving as a data point for investors following the company.
Form DEF 14A Roivant Sciences Ltd. For: 29 July By Investing.com
This article announces the filing of Form DEF 14A by Roivant Sciences Ltd. for July 29, 2026. The content is primarily a placeholder, indicating the availability of this specific SEC filing on Investing.com. It is a brief, informative post without detailed financial analysis or reporting beyond the announcement itself.
Form 4 Roivant Sciences Ltd. For: 29 July By Investing.com
This article announces the filing of a Form 4 by Roivant Sciences Ltd. on July 29, as reported by Investing.com. It includes a standard disclaimer about the high risks involved in trading financial instruments and cryptocurrencies. Trading on margin and the volatility of prices are highlighted, along with the recommendation to seek professional advice before investing.
Form 4 Roivant Sciences Ltd. For: 29 July By Investing.com
This article provides details about a Form 4 filing for Roivant Sciences Ltd. on July 29. It briefly mentions the company's stock symbol (ROIV) and its recent percentage change. The content primarily focuses on presenting the Form 4 information without further elaboration.
Roivant Sciences (ROIV) president sells 200k shares after exercising options
Eric Venker, President of Roivant Sciences (ROIV) and CEO of Immunovant, exercised 200,000 stock options at $3.85 per share on July 27, 2026. Following this exercise, he sold all 200,000 common shares at a weighted average price of $34.95 per share, under a Rule 10b5-1 trading plan. After these transactions, Venker still holds 4,044,834 stock options set to expire in 2032 and 1,613,063 direct common shares.
